JP2024521185A5 - - Google Patents

Info

Publication number
JP2024521185A5
JP2024521185A5 JP2023573206A JP2023573206A JP2024521185A5 JP 2024521185 A5 JP2024521185 A5 JP 2024521185A5 JP 2023573206 A JP2023573206 A JP 2023573206A JP 2023573206 A JP2023573206 A JP 2023573206A JP 2024521185 A5 JP2024521185 A5 JP 2024521185A5
Authority
JP
Japan
Prior art keywords
cells
seq
antibody
polynucleotide
immune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023573206A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024521185A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/031144 external-priority patent/WO2022251504A2/en
Publication of JP2024521185A publication Critical patent/JP2024521185A/ja
Publication of JP2024521185A5 publication Critical patent/JP2024521185A5/ja
Pending legal-status Critical Current

Links

JP2023573206A 2021-05-26 2022-05-26 Ｈｌａ－ｇ陽性癌を標的とするキメラ抗原受容体 Pending JP2024521185A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163193515P 2021-05-26 2021-05-26
US63/193,515 2021-05-26
PCT/US2022/031144 WO2022251504A2 (en) 2021-05-26 2022-05-26 Chimeric antigen receptor to target hla-g-positive cancers

Publications (2)

Publication Number Publication Date
JP2024521185A JP2024521185A (ja) 2024-05-28
JP2024521185A5 true JP2024521185A5 (enExample) 2025-05-26

Family

ID=84230349

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023573206A Pending JP2024521185A (ja) 2021-05-26 2022-05-26 Ｈｌａ－ｇ陽性癌を標的とするキメラ抗原受容体

Country Status (7)

Country Link
US (1) US20240252539A1 (enExample)
EP (1) EP4347635A4 (enExample)
JP (1) JP2024521185A (enExample)
CN (1) CN118234744A (enExample)
AU (1) AU2022280063A1 (enExample)
CA (1) CA3221568A1 (enExample)
WO (1) WO2022251504A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4419128A4 (en) * 2021-10-20 2025-10-01 Univ Texas NK CELL ENGINEERING WITH CAR CONSTRUCTION WITH OPTIMAL SIGNALING
CN119569892A (zh) * 2023-09-06 2025-03-07 上海恩凯细胞技术有限公司 特异性靶向肿瘤非经典hla分子的嵌合抗原受体的应用
WO2025180505A1 (zh) * 2024-03-01 2025-09-04 上海君赛生物科技有限公司 包含cd62l胞内结构域的细胞表面受体
WO2025180504A1 (zh) * 2024-03-01 2025-09-04 上海君赛生物科技有限公司 表达辅助受体的细胞
CN118420786B (zh) * 2024-06-12 2025-10-17 浙江大学医学院附属第一医院(浙江省第一医院) 一种靶向her2和hla-g的双特异性嵌合抗原受体及其应用
CN119264271B (zh) * 2024-10-08 2025-05-09 北京市神经外科研究所 一种nk细胞特异性的嵌合抗原受体及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002228745A1 (en) * 2000-10-23 2002-05-06 Rajagopalan, Sumati Antibodies and other ligands directed against kir2dl4 receptor for production of interferon gamma
WO2005102456A1 (en) * 2004-03-27 2005-11-03 The Arizona Board Of Regents On Behalf Of The University Of Arizona Composition and method for cancer treatment
CA2969384A1 (en) * 2014-12-17 2016-06-23 Cellectis Inhibitory chimeric antigen receptor (icar or n-car) expressing non-t cell transduction domain
AU2016243128A1 (en) * 2015-03-27 2017-11-02 University Of Southern California HLA-G as a novel target for CAR T-cell immunotherapy
CN108383914A (zh) * 2018-02-23 2018-08-10 北京美康基免生物科技有限公司 一种基于cd19的嵌合抗原受体及其应用
AR115052A1 (es) * 2018-04-18 2020-11-25 Hoffmann La Roche Anticuerpos multiespecíficos y utilización de los mismos
WO2020009868A1 (en) * 2018-07-03 2020-01-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-slamf7 chimeric antigen receptors
MX2021002316A (es) * 2018-08-31 2021-07-15 Invectys SA Receptores de antígeno quimérico frente a múltiples isoformas de hla-g.
TWI694083B (zh) * 2018-09-17 2020-05-21 中國醫藥大學附設醫院 嵌合抗原受體、核酸、嵌合抗原受體表達質體、表達嵌合抗原受體細胞、其用途以及用於治療癌症之醫藥組合物

Similar Documents

Publication Publication Date Title
JP2024521185A5 (enExample)
US12404492B2 (en) Methods for enhancing efficacy of therapeutic immune cells
KR102363191B1 (ko) 면역치료용 조성물 및 방법
JP2024527559A5 (enExample)
Zhang et al. Mesenchymal stromal cells as vehicles of tetravalent bispecific Tandab (CD3/CD19) for the treatment of B cell lymphoma combined with IDO pathway inhibitor D-1-methyl-tryptophan
JP6285553B2 (ja) 抗ｃｄ３０キメラ抗原受容体およびその使用
Kagamu et al. Isolation based on L-selectin expression of immune effector T cells derived from tumor-draining lymph nodes
JP2021509287A (ja) キメラ抗原受容体（ｃａｒ）またはトランスジェニックｔ細胞受容体（ｔｃｒ）の発現のためのウイルスベクターで細胞を形質導入するための方法
WO2016054520A2 (en) Engineered cell surface proteins and uses thereof
CN111386125A (zh) 多肽
JP2024525492A5 (enExample)
KR20200019231A (ko) 조절 면역 세포를 제조하기 위한 방법 및 이의 용도
JP2024514203A5 (enExample)
WO2023193660A1 (zh) 增强型嵌合抗原受体及其应用
KR20210033941A (ko) 개선된 t-세포 요법
JP2024525609A5 (enExample)
JP2023540551A (ja) 免疫療法組成物
JP2025503546A5 (enExample)
Tsujimoto et al. Plasma cells induce apoptosis of pre-B cells by interacting with bone marrow stromal cells
JP2024504164A5 (enExample)
US20220056411A1 (en) Methods for isolating cd8+ selected t cells
Haas et al. Bispecific antibodies increase T-cell stimulatory capacity in vitro of human autologous virus-modified tumor vaccine.
US20250361294A1 (en) Nucleic acid sequence encoding a chimeric antigen natural killer cell receptor (nk-car), polypeptide of said nk-car, vector comprising said nucleic acid sequence, in vitro method of obtaining an nk cell, use of said nucleic acid sequence, polypeptide or vector, and pharmaceutical composition
WO2021101467A1 (en) A method for redesign and expansion of nk92 cells for use in immunotherapy
JP2024539126A5 (enExample)